Mezagitamab - Takeda
Alternative Names: Anti-CD38 mAb; TAK-079Latest Information Update: 28 Jun 2025
At a glance
- Originator Takeda
- Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Idiopathic thrombocytopenic purpura
- Phase II Multiple myeloma; Myasthenia gravis
- Phase I/II Systemic lupus erythematosus
- No development reported IgA nephropathy
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in IgA-nephropathy in USA (SC, Injection)
- 09 May 2025 Takeda plans a phase III trial for IgA nephropathy (Combination therapy, Treatment-experienced) (SC, Injection) in August 2025 (NCT06963827) (EUCT2025-520825-19-00)
- 06 May 2025 Takeda plans a phase III trial for Idiopathic thrombocytopenic purpura (SC), in August 2025 (NCT06948318) (EUCT2025-521692-31-00)